Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis

Natalizumab (Nat) is a humanized monoclonal antibody used for the treatment of relapsing multiple sclerosis (MS). Nat inhibits lymphocyte migration via the blood brain barrier (BBB) by blockage of an integrin adhesion molecule, very late antigen 4. During the phase III clinical trials, it was shown...

Full description

Bibliographic Details
Main Authors:	Robert Hoepner, Simon Faissner, Anke Salmen, Ralf Gold, Andrew Chan
Format:	Article
Language:	English
Published:	SAGE Publishing 2014-01-01
Series:	Journal of Central Nervous System Disease
Online Access:	https://doi.org/10.4137/JCNSD.S14049

Similar Items

Progressive multiple sclerosis: latest therapeutic developments and future directions
by: Simon Faissner, et al.
Published: (2019-09-01)

Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis
by: Robert Hoepner, et al.
Published: (2022-03-01)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
by: Ilaria Callegari, et al.
Published: (2023-01-01)

Real-world evidence and patient preference for subcutaneous intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis – initial results from the observational SISTER study
by: Ralf Gold, et al.
Published: (2024-04-01)

Best practice in the use of natalizumab in multiple sclerosis
by: Óscar Fernández
Published: (2013-03-01)

Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System
by: Maximilian Pistor, et al.
Published: (2022-10-01)

Natalizumab in patients with multiple sclerosis in Colombia: a case series
by: Juan Raúl García Bonitto, et al.
Published: (2020-06-01)

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
by: Smaranda Maier, et al.
Published: (2020-10-01)

Natalizumab: increased vigilance is required in treating patients with multiple sclerosis
by: Michael K. Racke, et al.
Published: (2008-11-01)

Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis
by: Diogo G. Corrêa, et al.
Published: (2023-08-01)

Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC)
by: E. V. Popova, et al.
Published: (2014-12-01)

The effectiveness of Natalizumab on MRI outcome measures in patients with relapsing multiple sclerosis
by: Dalton, C, et al.
Published: (2003)

Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.
by: Karen Yao, et al.
Published: (2008-01-01)

The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
by: Roberto De Masi, et al.
Published: (2021-01-01)

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis
by: Pietro Iaffaldano, et al.
Published: (2024-08-01)

Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis.
by: Ragnhild Reehorst Lereim, et al.
Published: (2024-01-01)

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
by: Ranjani Ganapathy Subramanian, et al.
Published: (2021-11-01)

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
by: Planas R, et al.
Published: (2014-04-01)

Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
by: Stephenson Judith J, et al.
Published: (2012-12-01)

Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report
by: Constantin Gabriela, et al.
Published: (2010-09-01)

Multiple Sclerosis Treatment with Natalizumab: Analysis of a Hospital-Based Cohort
by: Ana Teresa Carvalho, et al.
Published: (2014-08-01)

Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
by: Kathy Khoy, et al.
Published: (2020-09-01)

Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis
by: Finn Sellebjerg, et al.
Published: (2016-01-01)

Insight into motor fatigue mechanisms in natalizumab treated multiple sclerosis patients with wearing off
by: Giorgio Leodori, et al.
Published: (2024-07-01)

Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates
by: Arwa Rekik, et al.
Published: (2022-05-01)

An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations
by: Kornek B
Published: (2015-05-01)

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
by: Julia Krämer, et al.
Published: (2017-01-01)

Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers
by: Enedina Maria Lobato de Oliveira, et al.
Published: (2015-09-01)

The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives
by: Rehana Z Hussain, et al.
Published: (2022-08-01)

JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients
by: Mancuso Roberta, et al.
Published: (2012-12-01)

Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients
by: Jan W. Traub, et al.
Published: (2019-11-01)

Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies
by: Helmut Butzkueven, et al.
Published: (2024-01-01)

Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis
by: Véronique Ferret-Sena, et al.
Published: (2016-01-01)

3 Managing disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis
by: Nevin John, et al.
Published: (2024-08-01)

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
by: Gatzonis Stylianos, et al.
Published: (2009-08-01)

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
by: Diego Cadavid, et al.
Published: (2013-01-01)

Eomesodermin-expressing CD4+ Th cells and association with pregnancy in multiple sclerosis
by: Simon Faissner, et al.
Published: (2024-02-01)

A comparison of natalizumab’s effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients
by: Marco Puthenparampil, et al.
Published: (2024-11-01)

Early Magnetic Resonance Detection of Natalizumab-Related Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Sclerosis
by: Guglielmo Manenti, et al.
Published: (2013-01-01)

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
by: Tim Sinnecker, et al.
Published: (2016-01-01)